Background: Acute myeloid leukemia (AML) is initiated and maintained by a unique, small subset of leukemia stem cells (LSCs). LSCs are characterized by unrestricted self-renewal and contribute to the malignancy of leukemia. Aberrant protein fucosylation is associated with AML progression. However, it is still less understood that the miR-29b/Sp1/FUT4 crosstalk involved in the fucosylation-mediated LSCs malignancy in AML. Methods: AML cell lines were sorted by magnetic microbeads to obtain the CD34 + CD38-sub-population. The key biomarkers for LSCs were identified by flow cytometry. Fucosyltransferase genes were screened by qRT-PCR, and FUT4 was focused. Effect of FUT4 on LSCs malignancy was determined by CCK8 assay, sphere formation assay, immunofluorescence staining, apoptosis and in vivo xenografts experiments. The linkage of FUT4 promoter and Sp1 was confirmed by dual-luciferase reporter gene assay. ChIP-PCR assay was used to show the directly binding of Sp1 and FUT4 promoter. Activity of Wnt//β-catenin pathway was determined by western blot. Overall survival curves were diagrammed by Kaplan-Meier analysis.
Background
Acute myeloid leukemia (AML) is an aggressive malignancy of the hematopoietic system, which is characterized by the clonal proliferation and differentiation into immature hematopoietic cells of dysfunctional myeloid precursors [1] . Despite progress made in the treatment of AML, most patients suffer relapses of the disease [2] . AML is typically a stem cell-driven disease, and the existence of leukemia stem cells (LSCs) is first identified (CD34 + CD38-) by JE Dick in 1994 [3] . Accumulating evidence shows that LSCs drive the initiation and perpetuation of AML, whereas show less sensitive to chemotherapy. LSCs are major clinical factors in disease progression and relapse, and increasingly being used as critical target for clinical therapeutic intervention [4, 5] . LSCs also exhibit stem cell-like characteristics such as the capacity for self-renewal, multi-potent differentiation potential and relative quiescence [6] . Therefore, it is important to target these malignant cells and investigate the intricate mechanisms to improve outcomes of AML patients.
Glycosylation is arguably the most abundant and complicated form of post-translational modification found in mammalian cells. Fucosylation is one of the most important types of glycosylation in cancer. Aberrant fucosylation of proteins is a well-known hallmark of cancer and represents a valuable source of cells interaction [7] . All fucosylation reactions in cells are catalyzed by fucosyltransferases (FUTs). So far, 13 different FUTs have been identified in the human genome, including FUT1 to 11, protein O-fucosyltransferase 1 (POFUT1), and POFUT2 [8] . FUT4 cDNA isolated from the HL-60 cell corresponds to myeloid type fucosyltransferase [9] . FUT4 mRNA was also highly expressed in both colon adenocarcinoma and myeloid cell lines [9, 10] . However, the exact molecular function of FUT4 during AML progression and whether FUT4 could be a potential therapeutic target remains largely unknown.
Specificity protein 1 (Sp1) is a sequence-specific DNA-binding protein, which is involved in the activation and regulation of cellular transcription. Thus, Sp1 is an essential transcription factor for many genes [11] . Abnormal Sp1 expression and activation are considered to promote human cancer initiation and progression, including leukemia. Evidence demonstrates that Sp1 modulates drug resistance of LSCs by regulating survivin expression [12] , and that Sp1 drives DHX15 expression in acute lymphoblastic leukemia [13] . Nevertheless, the role of SP1 driving FUT4 transcription in AML LSCs has not been clarified yet.
In recent years, a number of studies on prognostic markers in AML have focused on microRNAs (miRNAs), which lack protein-coding potential. MiRNAs are approximately 22 nucleotides in length, which inhibit transcription through binding to the 3′-UTR of target mRNA [14] . MiRNAs are also important regulators of hematopoiesis, and altered miRNAs expression are strongly associated with the pathogenesis of hematologic malignancies [15] . Among the reported miRNAs, the lower expression of miR-34c-5p in LSCs is closely correlated with the adverse prognosis and poor responses to therapy of AML patients [16] . MiR-99 is highly expressed in hematopoietic stem cells (HSCs) and LSCs, and regulates self-renewal in both HSCs and LSCs of AML [17] . Although several miRNAs have been reported to regulate LSCs malignancy of AML, the specific role of fucosylation that modulates LSCs malignancy of AML by miR-29b directly targeting Sp1 to drive FUT4 is not well understood.
In the present study, the expression pattern of FUTs in LSCs was examined, and the increased level of FUT4 in LSCs was positively associated with AML malignancy. MiR-29b mediated Sp1 expression, which further facilitated FUT4 level in LSCs. Furthermore, the underlying mechanism involved in miR-29b/Sp1/FUT4-regulated malignancy through CD44 fucosylation via Wnt/β-catenin pathway was explored in LSCs of AML.
Materials and methods

Cell culture and clinical samples
The AML cell lines, KG-1a was obtained from the ATCC cell bank, while MOLM13 was purchased from the German Collection of Microorganisms and Cell Culture (DSMZ, Braunschweig, Germany). Cells were cultured in RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin (Gibco) at 37°C in air containing 5% CO 2 . Cells were separated and enriched for CD34 + CD38-cells using magnetic microbeads (MiltenyiBiotec, Auburn, CA, USA) and labeled with CD34-FITC, CD38-PE, or isotype control antibodies.
Peripheral blood mononuclear cells (PBMCs) were collected from 50 newly diagnosed AML patients comprising 28 males and 22 females with age ranging from 18 to 65 years (median age of 38.8 years). The samples were obtained from the First Affiliated Hospital of Dalian Medical University (Dalian, China) from Jan 2016 to Feb 2018. Our work was approved by the Institutional Ethics Committee of the First Affiliated Hospital of Dalian Medical University (Ethics Reference NO: YJ-KY-FB-2016-45). PBMCs of AML were obtained by Ficoll-Hypaque density gradient centrifugation (Sigma-Aldrich) and were further cultured in plastic dishes to remove adherent cells at 37°C for 24 h. PBMCs cells were purified for CD34 + CD38-cells using magnetic microbeads. The purity of enriched CD34 + CD38-was evaluated by staining with FITC-conjugated anti-CD34 and CD38-PE. By adding B27 (1:50; Life Technologies, Carlsbad, CA, USA), 10 ng/mL basic fibroblast growth factor (bFGF) and 20 ng/mL epidermal growth factor (EGF), the CD34 + CD38-cells were maintained in DMEM/F12K medium. All cells were incubated at 37°C in a humidified chamber with 5% CO 2 .
Quantitative real-time PCR
Purified RNAs were extracted from PBMC samples and AML cell lines using Trizol reagent (Invitrogen, USA). First-strand cDNA synthesis was synthesized using a PrimeScript™ RT reagent Kit (TaKaRa). The cDNA synthesis was performed at 37°C for 60 min after heat at 95°C for 10 min. The cDNA was amplified using SYBRPremix Ex Taq™ II (TaKaRa). MiR-29b was normalized to U6 and FUTs mRNA was normalized to GAPDH. The primers were supplied in Additional file 5 Table S1 . All reactions were performed in triplicate.
Western blot
20 μg protein extract were separated on 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5% skimmed milk and followed by incubating with the primary antibody (FUT4, AP12067b, Abgent; cleaved caspase-3 ab2302, Abcam; cleaved PARP, ab4830, Abcam; Sp1, ab13370, Abcam; CD44, ab157107, Abcam; GSK-3β, 22,104-1-AP, Proteintech; p-GSK-3β, 22,104-1-AP, Proteintech; β-catenin, 51,067-2-AP, Proteintech; CyclinD1, 60,186-1-Ig, Proteintech; GAPDH, AP7873a, Abgent) on a shaker overnight at 4°C. The membranes were then incubated with horseradish peroxidase-conjugated secondary antibody (rabbit IgG, 1/1000 diluted; UK). A GAPDH antibody (1/200 diluted; Santa Cruz Biotech) was used as a control. All bands were detected using ECL Western blot kit (Amersham Biosciences, UK). The bands were measured with LabWorks (TM ver4.6, UVP, BioImaging systems).
Flow cytometry (FCM) analysis
Cells were placed in sterile conical tubes in aliquots of cells and stained with one of the FITC-CD34, FITC-CD38, FITC-CD13, FITC-CD33, FITC-CD123 and FITC-P-gp at a final concentration of 10 μg/ml. After repeated centrifugation at 1000 r/min, and labeled cells were resuspended in 0.2 ml PBS. The cells were analyzed with FACS flow cytometer (BectonDickinson, CA, USA).
The apoptosis assay was performed using Annexin-V-FITC apoptosis detection kit (BD, Franklin Lakes, NJ, USA). Apoptotic rate of the treated cells was determined by FACS, detecting the fluorescence of at least 10,000 cells of each sample. Each experiment was repeated in triplicate.
Methylcellulose colony formation assay
The colony-forming capacity of LSCs (CD34 + CD38-) of KG-1a and MOLM13 cells were measured using methylcellulose medium (Methocult GF M3534) according to the manufacturer's instructions. In brief, 2 × 10 3 cells were cultured in six-well plates with 1 mL of Methocult M3534 and 2 ml RPMI 1640 medium containing 10% FBS at 37°C for 10-14 days. CFU consisting of 40 or more cells were counted under microscope.
In vitro drug susceptibility assay
Drug susceptibility was measured using cell counting kit-8 (CCK-8; KeyGEN, Nanjing, China). The cells at density of 5000 cells/100 μl in 96-well culture plates were treated with different anticancer drugs ADR, Ara-C and paclitaxel for 48 h, respectively. CCK-8 solution (10 μl) was added to each well and the plate was incubated at 37°C in 5% CO 2 atmosphere. Absorbance at 450 nm (A450) was read on a microplate reader (168-1000 Model 680, Bio-Rad). The drug resistance was analyzed by comparing the OD values.
In vivo antitumor activity 5-week-old male athymic nude mice were purchased from the Model Animal Research Institute of Nanjing University. All animal study procedures were approved by the Committee on the Ethics of Animal Experiments of the Dalian Medical University. Approximately, 1 × 10 7 cells were injected subcutaneously into the right flank of each nude mouse, respectively. The mice were randomly divided into control and treatment groups. The treatment groups received 7 mg/kg ADR i.p. three times a week for 3 weeks. The mice were humanely killed and the tumors were photographed.
Oligonucleotide construction and dual luciferase assay FUT4 and miR-29b were cloned into the expression vector pcDNA3.1 (Invitrogen). MiR-29b mimic, negative control oligonucleotides (miR-NC), anti-miR-29b, negative control oligonucleotide (anti-miR-NC), ShFUT4, scramble shRNA of FUT4 (shSCR) were purchased from RiboBio (Guangzhou, China). The cells were seeded into 6-well plates and transfection was performed using lipofectamine 3000 (Invitrogen). The transfection efficiency was evaluated by qRT-PCR.
Cells were cultured overnight until 70-80% confluence. Next, HEK-293 T cells were co-transfected with pcDNA3.1 Wt-Sp1 or pcDNA3.1 mut-Sp1 and miR-29b or miR-NC, respectively. Lipofectamine 3000 (Invitrogen) was used according to the manufacturer's instructions. After 48 h, cells were harvested for luciferase detection using the dual-luciferase reporter gene assay system (Promega, Madison, WI, USA). Data were shown as the mean ± SD, and each experiment was performed thrice.
RNA immunoprecipitation (RIP) assay
RIP assay was performed using the Magna RIP™ RNA Binding Protein Immunoprecipitation Kit (Millipore, Bedford, MA, USA). Cells were collected (at 80-90% confluency) and lysed in complete RIPA buffer containing a protease inhibitor cocktail and RNase inhibitor. The cell extracts were incubated with RIP buffer containing magnetic bead conjugated with human anti-Ago2 antibody (Millipore) or mouse immunoglobulin G (IgG) control. The protein in the samples was digested with proteinase K and the immunoprecipitated RNA was obtained. The purified RNA was finally suffered qRT-PCR analysis to demonstrate the presence of the binding targets.
Immunohistochemistry (IHC)
The xenograft tumors were isolated and performed on paraffin-embedded section. The section was deparaffinized, rehydrated and then immersed in 3% hydrogen peroxide for 10 min to block endogenous peroxidase. The slices were incubated with primary anti-FUT4 or Ki67 antibody (1:200, Abcam) at 4°C overnight. The secondary streptavidin-HRP-conjugated antibody staining (1:1000, Santa Cruz Biotech) was performed for 1 h. The sections were counterstained with hematoxylin and cover-slipped.
Statistical analysis SPSS 13.0 was used to perform statistical analysis. Student's t-test was selected to determine the significance of differences among the examined groups. All experiments were performed in triplicate and results have been expressed as the mean ± standard deviation (SD). *P < 0.05 was considered to be statistically significant.
Results
Expressional profile of FUT family in CD34 + CD38-AML cell lines
LSCs were first enriched from KG-1a and MOLM13 cell lines by sorting a CD34 + CD38-cell population using magnetic microbeads. As shown in Fig. 1a , percentage of the CD34 + CD38-population was significantly increased after sorting from KG-1a (from 9.28 to 99.40%) and MOLM13 (from 6.53 to 98.81%) cells by flow cytometry. As shown in Fig. 1b , CD34 + CD38-KG-1a cells displayed positivity of the myeloid markers CD13 (93.46%), CD33 (98.18%) and CD123 (99.12%), as well as typical LSCs surface marker P-gp (96.64%). The positive rates of CD13 (97.69%), CD33 (95.95%), CD123 (98.51%) and P-gp (97.30%) were also higher in MOLM13 cells, suggesting that these cells were indeed LSCs and could be used for further studies.
To investigate whether fucosylation was involved in LSCs function, we performed qRT-PCR to analyze the levels of FUT gene family in the 2 sub-populations (CD34 + CD38-, the LSCs; the rest cells, named non-LSCs, including CD34 + CD38+, CD34-CD38+, CD34-CD38-) isolated from KG-1a and MOLM13 cells. As shown in Fig. 1c , remarkable increase of FUT4, FUT5, FUT8, FUT9 and FUT11 mRNAs were observed in LSCs compared with non-LSCs of KG-1a cells (*p < 0.05). In addition, FUT1 was higher in non-LSCs cells than LSCs. No statistically significant differences were found in the expression of FUT3, FUT6, FUT7 and FUT10 mRNAs. While FUT2 gene was almost absent in KG-1a cells. Additionally, FUT2, FUT4, FUT5, FUT8, FUT9 and FUT11 mRNAs were also found to be highly expressed in the LSC enriched fraction of MOLM13 cells (Fig. 1d ). Among these mRNAs, FUT4 was chosen for further exploration due to the extremely changes in AML cell lines. Furthermore, the FUT4 protein level was determined by western blot. As shown in Fig. 1e , decreased FUT4 level was shown in non-LSCs, comparing with the expression in LSCs of KG-1a cell lines. Interestingly, FUT4 also downregulated in non-LSCs of MOLM13 cell lines (Fig. 1f ) . These data indicated that the fucosylation of LSCs might correlate with the AML progression.
FUT4 mediates the progression of CD34 + CD38-AML cell lines in vitro and in vivo
To elucidate the direct effect of FUT4 on the progression involved in LSCs, FUT4 expression was down-regulated in CD34 + CD38-KG-1a and MOLM13 cell lines. As shown in Fig. 2a , the levels of FUT4 mRNA and protein were significantly decreased in shFUT4 transfectant compared to control. Furthermore, the fucosylation level, determined by LTL lectin, was significantly reduced in shFUT4-LSCs (Fig. 2b) . The proliferation of shFUT4-LSCs was decreased than the control cells (Fig. 2c) . Moreover, the reduced sphere formation ability was also proved by colony formation assay in cells transfected with shFUT4 (Fig. 2d) . As Ki67 was a key indicator of cell proliferation, the expression was further detected by immunofluorescence. Weaken Ki67 fluorescence intensity was shown in LSCs cells transfected with shFUT4 (Fig. 2e) . Meanwhile, enhanced apoptosis was shown in shFUT4-LSCs by FACS and TUNEL assays (Fig. 2f, g,) . Furthermore, cleaved caspase3 and PARP were both identified higher apoptosis. As shown in Fig. 2h , LSCs transfected with shFUT4 expressed increased levels of cleaved caspase3 and cleaved PARP, suggesting that knockdown of FUT4 induced apoptosis in LSCs.
Subsequently, to investigate whether FUT4 expression regulated drug resistance, the FUT4 knockdown LSCs were incubated in the presence of the chemotherapeutic agent ADR, Ara-C and Paclitaxel, which depicted a reduced capability to proliferate compared with their control groups (Fig. 2i) . P-gp intensity was reduced in shFUT4 LSCs group compared with the control (Fig. 2j) . To further assess the chemosensitivity to ADR in vivo, mouse xenograft studies were performed. In the shFUT4 LSCs model, down-expression of FUT4 significantly inhibited tumor growth. In the ADR treatment shFUT4 LSCs model, the primary tumor volume was found to decrease with ADR treatment, but overall the decrease was at a significantly faster rate than the untreated group (Fig. 2k) , demonstrating that down-regulation of FUT4 could overcome drug resistance in LSCs of AML. As shown in Fig. 2l , the expression of FUT4 and Ki67 in xenograft tumor was also verified by IHC staining. These results clearly demonstrated that FUT4 was responsible for AML progression via regulating fucosylation in LSCs.
Sp1 mediates FUT4 transcription and translation in CD34 + CD38-AML cell lines
To explore the internal mechanism involved in AML progression, the transcriptional regulation was investigated. Treated with transcriptional locker actinomycin D (Act D) or the translational inhibitor cycloheximide (CHX), FUT4 mRNA and protein levels were altered. For detail, FUT4 mRNA and protein levels were both Figure S1A ). Act D repressed the FUT4 mRNA level transcriptionally, which further impacted on the translational FUT4 protein level. However, in the treatment of CHX, the effective inhibitor of translation, FUT4 mRNA level was unvaried, while FUT4 protein level was gradually decreased dependent on the concentration of CHX in KG-1a-LSCs and MOLM13-LSCs (Additional file 1: Figure S1B ). The differential expression of Sp1 protein between LSCs and non-LSCs was firstly identified. As shown in Fig. 3a , Sp1 was higher in LSCs than non-LSCs of KG-1a cell lines. Additionally, Sp1 also upregulated in LSCs than non-LSCs of MOLM13 cell lines (Fig. 3b) . To further study the transcriptional regulation of FUT4 in LSCs, the promoter activity from the region − 2000 bp upstream of the transcription start site was shown. The full-length or fragments of relative FUT4 promoter position of was shown (Fig. 3c) . FUT4 promoter was fragmented into 4 overlapping segments (P1, P2, P3 and P4), and P3 segment contained a predictive Sp1 binding element (TBE: CAGGCGCGGT). By dual-luciferease reporter assay, FUT4 promoter bound with Sp1 directly (Fig. 3d) . Subsequently, P3 fragment was verified as the directly interacting element with wt-Sp1 sequence (Fig. 3e) . ChIP assay was performed to further identify the interaction between Sp1 and FUT4. ChIP with antibody against Sp1 cross-linked to the binding site cluster, showed an enrichment of the FUT4 promoter compared with the IgG control in LSCs of KG-1a and MOLM13 cells (Fig. 3f ) . Further exploration clarified that upregulated Sp1 bound with enriched FUT4 promoter, while siSp1 attenuated the binding affinity with FUT4 promoter (Fig. 3g) . These results revealed that Sp1 mediated transcription and translation of FUT4, which formed a positive regulatory network in KG1a-LSCs. 
Sp1 is a direct target of miR-29b and positively regulates FUT4 transcriptional level in CD34 + CD38-AML cell lines
Bioinformatic analysis predicts that Sp1 is a direct target of miR-29b (starBase: http://starbase.sysu.edu.cn). The expression of miR-29b was examined using qRT-PCR in two pairs of CD34 + CD38-AML cell lines. MiR-29b was expressed at lower level in the KG-1a-LSCs and MOLM13-LSCs compared with non-LSCs (Fig. 4a) , indicating that miR-29b was frequently down-regulated in LSCs of AML. A significant negative correlation was observed between miR-29b and Sp1 mRNA (r = − 0.7875, p < 0.0001, Fig. 4b ) in LSCs of AML patients. According to the bioinformatic analysis, the predicted binding sites were determined. Dual-luciferase reporter gene assay confirmed that Sp1 was a direct target of miR-29b (Fig. 4c) . KG-1a-LSCs (Fig. 4d) and MOLM13-LSCs (Additional file 2: Figure S2A ) were transiently transfected with miR-29b mimic or inhibitor to study the effect of miR-29b on Sp1 expression. MiR-29b mimic significantly inhibited Sp1 level, while anti-miR-29b promoted Sp1 expression in KG-1a LSCs (Fig. 4e ) and MOLM13 LSCs (Additional file 2: Figure S2B ), which accordingly influenced FUT4 expression of KG-1a LSCs (Fig. 4f, g ) and MOLM13 LSCs (Additional file 2: Figure   Fig. 3 Sp1 mediates FUT4 transcription and translation in CD34 + CD38-AML cell lines. a Sp1 protein level was determined by western blot between LSCs and non-LSCs of KG-1a cells. b Sp1 protein level was determined by western blot between LSCs and non-LSCs of MOLM13 cells. c The promoters of FUT4 were presented, and the predicted transcription factor binding elements (TBE) were indicated. The fragments of FUT4 promoter were investigated. d Directly binding between Sp1 and FUT4 promoter was verified by dual-luciferase reporter assays. e The P3 fragment of FUT4 promoter showed directly interaction with Sp1 by dual-luciferase reporter assays. f The binding of FUT4 promoter and Sp1 was further explored by ChIP-PCR assays. g With the mediation of Sp1, the binding affinity between Sp1 and FUT4 promoter was detected in AML cell lines. Data are the means ± SD of triplicate determinants (*P < 0.05) S2C, S2D). Upon mediation of miR-29b level, we also examined the binding affinity between Sp1 and FUT4 promoter (Fig. 4h ). Higher miR-29b level in LSCs partially repressed the binding of FUT4 and Sp1 through targeting Sp1.
To investigate the relationships among miR-29b, Sp1 and FUT4 and their effects on the progression of LSCs, KG1a-LSCs were transfected with anti-miR-29b and anti-miR-NC, siSp1 and control siRNA. Compared with control, the mRNA level of FUT4 was significantly up-regulated by anti-miR-29b and was significantly down-regulated by siSp1 (Fig. 4i, *p < 0.05) . Co-transfection of anti-miR-29b and siSp1 showed that anti-miR-29b partially restored the suppression of FUT4 level by siSp1 (Fig. 4i) . Similar results were also detected by western blot in KG1a-LSCs (Fig. 4i) . Furthermore, fucosylation level (detected by FITC-LTL) on the LSCs surface showed the same tendency (Fig. 4j) . In addition, the potential function of miR-29b/Sp1/FUT4 pathway to KG1a-LSCs development was evaluated. KG-1a-LSCs were transfected with anti-miR-29b and the colony formation capacity and drug resistance were increased (Fig. 4k, l) . Co-transfection of anti-miR-29b and siSp1, the anti-miR-29b promoted the proliferation and drug resistance suppressed by siSp1 in LSCs. As shown Fig. 4k , anti-miR-29b reduced KG1a-LSCs apoptosis, whereas siSp1 promoted apoptosis. Co-transfection of anti-miR-29b and siSp1 showed that anti-miR-29b restored apoptosis promoted by siSp1. These results demonstrated the function and regulatory mechanism of miR-29b/Sp1/FUT4 axis in the development of AML LSCs.
MiR-29b/Sp1/FUT4 crosstalk regulates CD44 fucosylation and activates Wnt/β-catenin pathway in CD34 + CD38-AML cell lines More recent studies have shed light on the function of fucosylated CD44, which could modulate CD44-mediated intracellular signaling. The LTL-CD44 and total CD44 protein levels were determined by western blot between LSCs and non-LSCs of KG-1a (Additional file 3: Figure S3A ) and MOLM13 (Additional file 3: Figure  S3B ). Differential levels of LTL-CD44 and total CD44 were shown in the cell lines, demonstrating the crucial effect of fucosylation and CD44 on LSCs. To clarify the internal mechanism, fucosylated glycan binding lectin LTL agarose pull-down was performed (Fig. 5a ). KG-1a-LSCs and MOLM13-LSCs transfected with shFUT4 revealed decreased LTL-binding CD44 level. However, the total extracted proteins of LSCs showed no changes, illustrating the altered fucosylation of LSCs. By modulating miR-29b and Sp1 levels in LSCs-KG-1a and LSCs-MOLM13, LTL-CD44 levels were altered, while total CD44 protein level was not altered (Fig. 5b) . We also checked the differential activity of Wnt/β-catenin signaling between LSCs and non-LSCs in KG-1a (Additional file 3: Figure S3C ) and MOLM13 cell lines (Additional file 3: Figure S3D ). As shown in Fig. 5c , the Wnt/β-catenin signaling was inactivated by CD44-blocking with the specific antibody in KG1a-LSCs and MOLM13-LSCs. Manipulation of miR-29b and Sp1 could mediate the main molecules expression of Wnt/ β-catenin pathway in LSCs (Fig. 5d) . Overexpression of miR-29b inhibited Wnt/β-catenin pathway activity in LSCs. Up-regulated Sp1 triggered the activation of the pathway. However, co-transfection of miR-29b and Sp1 in LSCs significantly reversed the pathway activity compared to the LSCs transfected with miR-29b or Sp1 alone. In addition, modulation of miR-29b and Sp1 affected FUT4 level, which in consequence regulated fucosylation of CD44. These data suggested that miR-29b/ Sp1/FUT4 regulated CD44 fucosylation, which promoted the phosphorylation of downstream signaling.
To understand the significance of Wnt/β-catenin pathway in AML progression, treatment with Wnt/β-catenin inhibitor (DKK) were analyzed in LSCs. Phosphorylated GSK-3β (p-GSK-3β) was partially repressed with the treatment of DKK, while total GSK-3β was not altered compared with DMSO group (Fig. 5e) . Furthermore, β-catenin and cyclinD1 were also inhibited with the DKK treatment. To analyze the potential effect of shFUT4 on the cascade, we treated the LSCs with DKK and shFUT4. Interestingly, the activation of Wnt/β-catenin pathway was largely suppressed in LSCs treated with DKK and shFUT4 in comparison with the DMSO or DKK group. Co-treatment of DKK and shFUT4 enhanced the inhibitory roles on p-GSK-3β, β-catenin and cyclinD1 protein levels, while total GSK-3β was not affected. Accordingly, LSCs were treated with DKK and the colony formation capacity was decreased (Fig. 5f) , and Ki67 intensity was also attenuated (Fig. 5g) . More interestingly, the proliferative ability (including colony formation capacity and Ki67 intensity) was further repressed through LTL blocking, suggesting that targeting Wnt/β-catenin cascade and fucosylation could be potential targets to prevent LSCs malignant proliferation. Treatment with DKK induced apoptosis in LSCs (Fig. 5h,  i) . Additionally, combination of DKK and LTL induced higher apoptotic rate of LSCs-KG-1a. Here, our results suggested that miR-29b/Sp1/FUT4 could modulate AML progression possibly by affecting fucosylation via CD44/Wnt/β-catenin activation.
High expression of FUT4 and Sp1 in CD34 + CD38-AML samples correlates with poor survival outcomes
To investigate the clinical relevance of FUT4 and Sp1, PBMCs from 50 AML patients were isolated to directly compare FUT4 and Sp1 levels in paired CD34 + CD38-LSCs and non-LSCs (the rest cells). The group of primary CD34 + CD38-LSCs from AML patients showed significantly elevated FUT4 and Sp1 expression compared to non-LSCs (Fig. 6a) . Furthermore, miR-29b expression was further determined in AML patients, showing higher level in non-LSCs than the LSCs (Fig. 6a) . Accordingly, direct comparison of FUT4 and Sp1 protein levels in 5 paired LSCs and non-LSCs showed similar trends for these mRNA levels (Fig. 6b) . On the basis of the above observations, we next investigated whether FUT4 was expressed consistently with Sp1 in CD34 + CD38-AML patient samples. Linear regression analysis demonstrated a positive correlation between the mRNA levels of both FUT4 and Sp1 (r = 0.8467, *p < 0.0001,) in CD34 + CD38-AML samples (Fig. 6c) . The Kaplan-Meier method was also used to analyze the association of mRNA levels of FUT4 and Sp1 with overall survival (OS) in AML patients. The results showed that, compared with patients with low FUT4 and Sp1 expression, OS of patients with high FUT4 and Sp1 expression significantly decreased (*p < 0.05; Fig. 6d ). In addition, the percentage of LSCs in AML patients were also detected (Additional file 4: Figure S4 ). The results indicated that FUT4 and Sp1 displayed a potential clinical utility to monitor the progression of AML.
Discussion
AML is a lethal form of hematologic malignancy, typically of stem or progenitor cell origin. LSCs are capable of self-renewal and differentiation into malignant blasts, and are resistant to standard chemotherapy agents [18] . Effectively targeting LSCs are expected to greatly improve clinical relapse and overall survival rates of AML. Here, we describe a critical role for miR-29b/Sp1/ FUT4 axis in the regulation of LSC malignancy via Wnt/ β-catenin pathway in AML.
FUTs family represents an important group of fucosyltransferases, which are at least partially responsible for Fig. 5 MiR-29b/Sp1/FUT4 crosstalk regulates CD44 fucosylation and activates Wnt/β-catenin pathway in CD34 + CD38-AML cell lines. a LTL-CD44 level was altered with mediation of FUT4, while total CD44 showed no changes. b Modulation of miR-29b and Sp1 caused the altered level of LTL-CD44, and showed no impacts on CD44 level. c With CD44 antibody and LTL treatment, the activity of Wnt/β-catenin pathway was inhibited in LSCs-KG-1a cells by western blot. d Co-transfection of anti-miR-29b and siSp1 also impacted the activation of the cascade by western blot. e Co-treatment of DKK and shFUT4 suppressed the pathway activity. f DKK and shFUT4 impacted the sphere formation ability of LSCs-KG-1a. LTL blocking assays also suppressed the proliferation. g Ki67 staining also indicated the attenuated proliferation of LSCs-KG-1a cells with the treatment DKK, shFUT4 or LTL blocking. h Apoptotic rates of LSCs-KG-1a were increased after DKK, shFUT4 treatment or LTL blocking by flow cytometry. i TUNEL staining confirmed the apoptotic occurrence. Data are the means ± SD of triplicate determinants (*P < 0.05) the generation of fucosylation features. Fucosylation is an important functional regulation of glycoproteins and is critical for the abnormal glycosylation during tumor progression. FUT4 is abnormally upregulated in different types of cancers, such as colorectal cancer [19] , breast cancer [20] and lung adenocarcinoma [21] , and the up-regulation of FUT4 is associated with tumor metastases, higher recurrence, and poorer survival in tumor patients. According to these findings, we speculate that FUT4 is a key factor in promoting malignant progression of tumors. However, it is still not clear whether abnormal fucosylation, mediated by FUT4, is an important issue in promoting LSCs procession of AML. In the current study, we reported that the expression profiles of FUT gene family were shown to be remodeled in LSCs and non-LSCs AML cell lines. Elevated levels of FUT4 have been observed in AML LSCs. High expression of FUT4 might contribute to the elevating fucosylation on LSCs surface. This result was consistent with the observation that altered fucosylation might be the specific biomarker of cancer stem cell (CSC)-like cells in pancreatic cancer [22] . In addition, the expression of the FUT4 gene was regulated in a cell type-specific manner. Suppressing FUT4 expression significantly inhibited LSCs proliferation, induced LSCs apoptosis, and sensitized LSCs to chemotherapy, supporting the functional involvement of fucosylation in AML LSCs development. However, LSCs type-specific transcriptional regulation of FUT4 was not well understood.
A number of factors have been directly or indirectly identified as regulating the FUT4 promoter, including cellular transcriptional activator Sp1. Sp1 is an essential transcription factor for cancer associated genes, and abnormal Sp1 expression and activation are thought to contribute to human cancer development and progression [23] . Recent research showed that Sp1 was significantly up-regulated and positively correlated with survivin in CD34+ AML patients [12] . SP1 is associated with dysregulated cell cycle arrest in multiple myeloma [24, 25] . FUT4 has a GC-rich DNA region in its promoter that is bound and upregulated by Sp1 [26] . We observed that FUT4 expression, which was involved in AML LSCs progression, was down-regulated by SP1 silencing. In contrast, Sp1 overexpression in LSCs was able to revert to FUT4 promoter binding activity, indicating that the high expression of FUT4 in AML LSCs was dependent on the trans-activation of Sp1 through positioning of the specific sequence sites.
There are many ways for regulating Sp1 expression, including miRNAs. Alterations in miRNA expression patterns and their respective targets have been documented in different types of leukemias, such as chronic lymphocytic leukemia [27] , AML [28] and ALL [29] , thus suggesting a possible correlation between miRNA expression status and the development of hematological malignancies. MiR-150 could interact with Sp1 3′ UTR to hamper AML progression regulated by long non-coding RNA zinc finger antisense 1 (ZFAS1) [30] . As Sp1 is also a bona fide target of miR-29b, the miR-29b silencing resulted in increased Sp1 in AML cells [31] . However, the role of miR-29b in the progression of AML LSCs remains unknown. We therefore investigated the expression of miR-29b and its target gene Sp1 in AML LSCs. MiR-29b levels were significantly elevated in AML LSCs compared with non-LSCs. A reciprocal relationship between miR-29b and Sp1 expression was found in LSCs, which displayed significantly higher levels of Sp1 expression despite elevated levels of miR-29b. Moreover, we also demonstrated that Sp1-mediated transcription at FUT4 promoter was positively regulated by miR-29b, providing a putative mechanism for the role of miR-29b/Sp1/FUT4 axis in AML LSCs progression. To prove this, KG1a-LSCs were co-transfected with anti-miR-29b and siSp1. The anti-miR-29b promoted the proliferation and drug resistance suppressed by siSp1, and restored apoptosis induced by siSp1 in LSCs. These results demonstrated the function and regulatory mechanism of miR-29b/Sp1/FUT4 axis in the development of AML LSCs.
Previous study has reported a role for fucosylation of CD44 in the direct regulation of receptor function, including membrane phosphorylation, ligand binding, and signal transduction [32, 33] . CD44 is a class I transmembrane glycoprotein, and is abundant in α-fucosylation, especially α-1, 2 and α-1, 3-linkage, in breast cancer cells [34] . Phenotypically, CD44 is used as a marker of cancer stem cells (CSCs) in many cancers. On functional level, a therapeutic approach using an activating monoclonal antibody directed to the adhesion molecule CD44 had been successfully used to eradicate human AML LSCs [35] . However, the fucosylated CD44 regulated by FUT4 in AML LSCs remains unclear. In this study, the biosynthesis of α-1, 3-fucosylation on glycoprotein CD44 was inhibited in AML LSCs by treated with shFUT4. No significant differences in the expression levels of CD44 on cell surface were found between the LSCs. Furthermore, CD44 exerts its function by activating Wnt signaling pathway [36] . The Wnt/β-catenin signal pathway is involved in regulating the development of LSCs in AML [37] . Here, we found that altered CD44 by CD44-blocking or manipulation of miR-29b and Sp1 mediated the main molecules expression of Wnt/β-catenin pathway in LSCs. As expected, the LSCs colony formation and drug resistance were attenuated, and apoptosis was induced in LSCs treated with DKK. Additionally, clinical analysis showed clearly that FUT4 and Sp1 were valuable biomarkers of LSCs for AML prognosis. Collectively, the promotional effects of miR-29b/Sp1/FUT4 regulatory axis on AML LSCs progression could be partially mediated through fucosylated CD44-mediated Wnt/β-catenin signaling.
Our investigation has identified a transcriptional regulatory miR-29b/Sp1/FUT4 network, which exerted critical effects on AML LSCs malignancy by regulating fucosylated CD44 via Wnt/β-catenin pathway. MiR-29b/ Sp1/FUT4 axis could be regarded as a diagnostic biomarker and therapeutic target for AML. 
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